TY - JOUR
T1 - Microelectronic array system for molecular diagnostic genotyping
T2 - Nanogen NanoChip® 400 and Molecular Biology Workstation
AU - Keen-Kim, Dianne
AU - Grody, Wayne W.
AU - Richards, C. Sue
N1 - Funding Information:
Dianne Keen-Kim is supported by training grants from the Tourette Syndrome Association and the NINDS-T32 NS48004. Wayne W Grody is a paid consultant for Nanogen, Inc.
PY - 2006
Y1 - 2006
N2 - Hundreds of gene mutations responsible for Mendelian disorders are currently tested in the clinical laboratory for pre- and postnatal diagnosis, carrier screening and presymptomatic testing. Since human genetic research is currently focused on determining the etiology of complex diseases, including heart disease, diabetes and neuropsychiatric traits, laboratorians will genotype increasing numbers of clinically relevant loci in the future. This will require accurate, high-throughput and cost-effective genotyping platforms, such as the DNA microarray. The Nanogen NanoChip® platforms employ hybridization-based technology, using fluorescent detection and electronic control of the target or probe, to obtain clear genotype signal relative to background, and increased flexibility relative to similar chip-based single nucleotide polymorphism genotyping platforms. The scope of this review is intended to describe the operating principle, chips and instrumentation, analyte-specific reagents, published assay protocols, assay development, and clinical use of the NanoChip platforms. It is beyond the scope of this review to describe the use of NanoChip platforms in basic research, and to compare it against all available clinical single nucleotide polymorphism genotyping applications and platforms.
AB - Hundreds of gene mutations responsible for Mendelian disorders are currently tested in the clinical laboratory for pre- and postnatal diagnosis, carrier screening and presymptomatic testing. Since human genetic research is currently focused on determining the etiology of complex diseases, including heart disease, diabetes and neuropsychiatric traits, laboratorians will genotype increasing numbers of clinically relevant loci in the future. This will require accurate, high-throughput and cost-effective genotyping platforms, such as the DNA microarray. The Nanogen NanoChip® platforms employ hybridization-based technology, using fluorescent detection and electronic control of the target or probe, to obtain clear genotype signal relative to background, and increased flexibility relative to similar chip-based single nucleotide polymorphism genotyping platforms. The scope of this review is intended to describe the operating principle, chips and instrumentation, analyte-specific reagents, published assay protocols, assay development, and clinical use of the NanoChip platforms. It is beyond the scope of this review to describe the use of NanoChip platforms in basic research, and to compare it against all available clinical single nucleotide polymorphism genotyping applications and platforms.
KW - Analyte-specific reagent
KW - Microarray
KW - Molecular biology workstation
KW - NanoChip®
KW - NanoChip® 400
KW - SNP genotyping
UR - http://www.scopus.com/inward/record.url?scp=33745962246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745962246&partnerID=8YFLogxK
U2 - 10.1586/14737159.6.3.287
DO - 10.1586/14737159.6.3.287
M3 - Review article
C2 - 16706733
AN - SCOPUS:33745962246
SN - 1473-7159
VL - 6
SP - 287
EP - 294
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
IS - 3
ER -